FDA approves Genentech’s Tecentriq as first-line monotherapy for certain people with metastatic NSCLC

FDA approves Genentech’s Tecentriq as first-line monotherapy for certain people with metastatic NSCLC

Source: 
Pharmaceutical Business Review
snippet: 


Genentech, a member of the Roche Group, announced that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating [IC] covering ≥ 10% of the tumor area [IC ≥ 10%]), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.